Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Corporate Update (January 2026)
26 slides from Crinetics Pharmaceuticals's corporate update, January 2026
Slide 1: Corporate Update
JANUARY 2026 Corporate Update
Slide 2: Forward Looking Statements and Legal Disclaimers
Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained
Slide 3: Today's Key Takeaways
Today’s Key Takeaways Strong commercial execution on PALSONIFY 1 demonstrated by robust metrics New atumelnant data demonstrate 2 promising profile for treatment of CAH Crinetics has multiple levers to drive long-term 3 value CRINETICS PHARMACEUTICALS | 3
Slide 4: Palsonify Launch Update
Palsonify Launch Update CRINETICS PHARMACEUTICALS | 4
Slide 5: Palsonify: Executing Phased Launch to Address Broader Acromegaly Patient Population
Palsonify: Executing Phased Launch to Address Broader Acromegaly Patient Population Switch & Naive Return to Care Diagnose 36,000 17,000 Undiagnosed 19,000 No Active 7,500 Follow-up 10,000 Recent Treatment 1,500 Discontinued 4,500 Treatment Naïve 3,000 Injectable SRL 2,500 Other Therapies Phase 1 Ph
Slide 6: Strong Commercial Fundamentals Reflect Early Launch Success
Strong Commercial Fundamentals Reflect Early Launch Success Patients Providers Payers Activated and Adopting with Recognizing Value Motivated Confidence Proposition >200 >125 ~50% / ~50% Enrollment Forms Unique Palsonify Reimbursed vs. Quickstart Prescribers for Newly Filled Bottles 22/22 Enrollment
Slide 7: Palsonify is Delivering Meaningful Patient Impact
Palsonify is Delivering Meaningful Patient Impact Megan David David Ashleigh Previously treated with combination of Previously treated with somatuline depot Previously treated with SRL injections, monthly and weekly injections, and is injections, then Mycapssa, and is now and is now on PALSONIFY. no
Slide 8: Atumelnant: Adult CAH Phase 2 & OLE Update
Atumelnant: Adult CAH Phase 2 & OLE Update CRINETICS PHARMACEUTICALS | 8
Slide 9: Atumelnant: Designed to Transform the Treatment of Congenital Adrenal Hyperplasia
Atumelnant: Designed to Transform the Treatment of Congenital Adrenal Hyperplasia Today’s Update • On track for a highly differentiated product profile: Atumelnant again resulted in markedly reduced A4 levels. These A4 reductions were sustained even as GC doses were reduced to the physiologic range
Slide 10: Atumelnant is Designed to Treat CAH, Reserving Glucocorticoid Use for Physiologic Replacement Only
Atumelnant is Designed to Treat CAH, Reserving Glucocorticoid Use for Physiologic Replacement Only Hypothalamic-Pituitary-Adrenal (HPA) Axis in CAH Stress Hypothalamus • Atumelnant is the first and only investigational Circadian once-daily, oral MC2R antagonist in clinical testing Clock • Selectivel
Slide 11: Unmet Medical Need: FDA Approved Adjunctive Treatment Does Not Maintain A4 Reductions
Unmet Medical Need: FDA Approved Adjunctive Treatment Does Not Maintain A4 Reductions As GC Dose Reduced Phase 3 FDA Approved CRF1 Antagonist Placebo (N=60) FDA Approved CRF1 Antagonist (N=122) Stable GC Dose 600 Mean Change from Baseline in A4 400 Data adapted from: Auchus R, et al. 200 N Engl J Me
Slide 12: Atumelnant Vision: Healthier Hormone Levels for People Living with CAH
Atumelnant Vision: Healthier Hormone Levels for People Living with CAH 2500 High A4 High A4 Androstenedione Level (A4) 2000 + + Normal GC High GC 1500 (ng/dL) 1000 Normal A4 500 + Normal High GC A4 + GC 0 5 10 15 20 25 Glucocorticoid (GC) Dose (Hydrocortisone Equivalent) (mg/m2/day) A single pill ta
Slide 13: Atumelnant Demonstrated Potential to Normalize A4 Levels and GC Dose
Atumelnant Demonstrated Potential to Normalize A4 Levels and GC Dose Goal 1: Reduction of A4 to Normal Levels Phase 2 Cohorts 1-3 demonstrate A4 normalization and improvement in signs and symptoms • Demonstrate rapid, sustained reduction of A4 to normal levels • Address hyperandrogenism, which can m
Slide 14: Phase 2 Clinical Study Designed to Validate Atumelnant's Profile
Phase 2 Clinical Study Designed to Validate Atumelnant’s Profile as Optimal Treatment for CAH Study Size: 4 cohorts, each 12 Cohort 1: 80 mg Once Daily with constant GC1 (n=11) weeks (N=38) Eligible subjects Key Eligibility Criteria: Cohort 2: 40 mg Once Daily with constant GC1 (n=11) • Male or fema
Slide 15: Rapid, Substantial and Sustained A4 Reductions, the Key Biomarker for CAH Disease Control
Rapid, Substantial and Sustained A4 Reductions, the Key Biomarker for CAH Disease Control GC Stable Dose, GC Dose Reduced, PM Atumelnant Dosing AM Atumelnant Dosing • In each of the four Phase 2 1800 cohorts, baseline A4 levels were 40 mg 80 mg 120 mg Cohort 4 80 mg significantly elevated (>1,000 N=
Slide 16: Robust A4 Reduction Maintained with AM Dosing and Sustained with GCs Reduced
Robust A4 Reduction Maintained with AM Dosing and Sustained with GCs Reduced to Physiologic Levels Morning Serum A4 Levels and GC Doses Over Time for Cohort 4 (80mg AM Dosing) Atumelnant GC Taper From Weeks 2-10 Stable GC Dose 14.0 Mean GC Dose (mg/m2/day) (SE) 1500 GC Dose 7/8 Achieved Mean (SE) of
Slide 17: Atumelnant Demonstrated a Highly Differentiated Profile for Treatment of CAH
Atumelnant Demonstrated a Highly Differentiated Profile for Treatment of CAH Phase 2 Cohort 4 Compared with FDA Approved CRF1 Antagonist • Investigational atumelnant Atumelnant Cohort 4 80 mg (AM/GC) (N=8) FDA Approved CRF1 Antagonist (N=122) maintained reductions of A4 while GC doses were reduced t
Slide 18: Open-Label Extension Reflects Real-Life Clinical Management of CAH Patients
Open-Label Extension Reflects Real-Life Clinical Management of CAH Patients with Atumelnant EOT EOS Screening Open-label Treatment (Up to 2 years) Follow up (4 weeks) (up to 4 weeks, 1 visit) Weeks 1-13 (4 visits)1 One visit every 3 months thereafter2 Dose GC dosing regimen Atumelnant + GC GC dosing
Slide 19: Open-Label Extension Study Confirms Reduction of A4 Levels while Lowering Glucocorticoid Doses
Open-Label Extension Study Confirms Reduction of A4 Levels while Lowering Glucocorticoid Doses 1400 Participant responses with ≥13-week data as of December 2025 data snapshot 1200 • A4 reduction: 72% median 1000 • Clinically meaningful GC 40 mg reduction achieved in just 13 weeks 800 • Median GC Red
Slide 20: Safety Summary for Phase 2 Study
Safety Summary for Phase 2 Study Summary of TEAEs by Preferred Term (Reported by ≥5% of Total Participants) 40 mg 80 mg 120 mg 80 mg (AM/GC) N=11 N=11 N=6 N=10 Preferred Term n (%) n (%) n (%) n (%) Participants with at Least One TEAE 8 (72.7) 8 (72.7) 5 (83.3) 10 (100) Headache 2 (18.2) 4 (36.4) 2
Slide 21: Atumelnant Continues to be Well Tolerated with No Serious Adverse Events Reported
Atumelnant Continues to be Well Tolerated with No Serious Adverse Events Reported Phase 2 (N=38¹) OLE (N=25 to date²) (GCs reduced) Cohort 1 – 3 (N=28) (Stable GC doses) • 7 participants treated ≥20 weeks of which 1 participant was treated • Well tolerated, no serious adverse events and >40 weeks no
Slide 22: Phase 3 Adult CAH Study Designed to Achieve Both A4 And GC Normalization
Phase 3 Adult CAH Study Designed to Achieve Both A4 And GC Normalization Key Eligibility Criteria (N = 150): • Male or female participants ≥ 18 to 75 years. • A4 >ULN1 with supraphysiologic GC dose (≥11 mg/m2/day) • Classic 21-hydroxylase deficiency • A4 >ULN1 with physiologic GC dose (<11 mg/m2/day
Slide 23: Cohort 4 and OLE Further Build Confidence that Atumelnant Could Set a New Paradigm for Care
Cohort 4 and OLE Further Build Confidence that Atumelnant Could Set a New Paradigm for Care P2 Cohort 4 P2 OLE P3 CALM-CAH Key Takeaways Duration of 12 weeks Up to 2 years 32 weeks • Longer duration of Phase 3 treatment o More time for participants to get to physiologic GC doses GC reduction Investi
Slide 24: Atumelnant Data to Date Show Promising Profile for the Treatment of CAH
Atumelnant Data to Date Show Promising Profile for the Treatment of CAH Goals Results Replicate reduction of A4 observed in 67% reduction in A4 in Cohort 4 consistent with the 70% Cohorts 1-3 (fixed supraphysiologic previously observed in Cohort 1 with stable GCs; 72% glucocorticoid doses) median re
Slide 25: Poised to Deliver Multiple Commercial & Clinical Catalysts in the Next 24+ Months
Poised to Deliver Multiple Commercial & Clinical Catalysts in the Next 24+ Months TODAY Commercial U.S. FDA Catalysts: U.S. Launch Trajectory Approval Clinical TouCAHn Balance-CAH (Peds) Calm-CAH (Adult) Catalysts: Cohort 1-3 Readout Cohort 4 + OLE Readout Phase 2 Preliminary Data Phase 3 Readout AD
Slide 26: Thank You
{Crinetics Thank You
Crinetics Pharmaceuticals — Corporate Update (January 2026) on 6ix